Compare KALA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALA | COCH |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.8M | 49.7M |
| IPO Year | 2017 | N/A |
| Metric | KALA | COCH |
|---|---|---|
| Price | $1.69 | $0.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $6.00 |
| AVG Volume (30 Days) | 142.2K | ★ 647.0K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.36 |
| 52 Week High | $20.58 | $1.89 |
| Indicator | KALA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 66.12 |
| Support Level | $0.32 | $0.64 |
| Resistance Level | $1.81 | $0.88 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 3.85 | 53.21 |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.